Hope to erase the blurry vision of age


Ever held a newspaper at arm’s length to read the fine print?

Then you might benefit from the development of eye drops that literally could change the way some 100 million Americans see.

The drops were developed by Encore Vision with support from the Tech Fort Worth-UNT Health Science Center Accelerator Lab. They treat presbyopia, a condition that causes blurry near vision as people age.

"Right now there is no medical treatment for presbyopia, just glasses or surgery," said Bill Burns, Encore Vision President and CEO. "And presbyopia is a condition that virtually everyone over 45 experiences."

The eye drops work by reducing stiffness in the eye lens that occurs with aging. By restoring flexibility, the drops allow the lens to thicken in the center, making it easier to focus on nearby objects.

"The drops are made from natural agents found in the body," Burns said. "So the body doesn’t have to figure out how to metabolize them, a key safety feature."

Burns turned to the TechFW-UNTHSC Accelerator Lab for help in the early stages of development. Having access to lab space, equipment and other facilities was a real benefit, he said.

"The resources available at the Accelerator Lab have proven to be an enormous asset to a start-up company like ours," he said. "The easy access to the vast treasure trove of publications, data and research was truly essential."

"Encore Vision was the right kind of company for the partnership represented by the TechFW-UNTHSC Accelerator Lab," said Joe Allred, Associate Vice President for Research and Innovation.
 
The way Encore Vision has progressed is a good example of how TechFW and UNTHSC provide much more than just space for Accelerator Lab clients, said Darlene Boudreaux, Executive Director of Tech Fort Worth.

"TechFW staff helped Bill put together a business model that would work, coached him on presenting a business that would interest the right investors, then put him in front of our Cowtown Angel Network," she said.

Encore Vision expects to move to human clinical trials by early next year. The therapeutic dosage has not been established, but Burns said the clinical program will help them determine dosing frequency and duration of treatment.

"Our intent is by using these drops daily, people can eliminate entirely or at least reduce their dependency on readers," he said.

Recent News

Mtawndy2mze
  • Community
|Apr 25, 2024

New TCOM-affiliated internal medicine residency at Paris Regional Health Gains ACGME approval

In a significant move to help address the growing primary care physician shortage in Texas, The University of North Texas Health Science Center at Fort Worth’s Texas College of Osteopathic Medicine and Paris Regional Health are now approved for a new Internal Medicine Residency Program. The Accre...
Amanda
  • On Campus
|Apr 24, 2024

HSC to host HIV Symposium

HIV remains a major global health issue, with an estimated 40 million people living with HIV worldwide. About 10 million of them, including about half of infected children, do not have access to treatment. From 9:30 a.m. to noon on Monday, health care providers working on the frontlines of the HIV ...
Community Health Worker Week
  • Our People
|Apr 19, 2024

Recognizing the important role of community health workers

In recognition of the important role of community health workers, their leadership and their impact on communities, Community Health Worker Week 2024 is being celebrated nationally April 22-28. The University of North Texas Health Science Center at Fort Worth School of Public Health’s State Hea...
Mtawndy2mze
  • Our People
|Apr 18, 2024

TCOM’s Dr. Lisa Nash honored with the 2024 Special Lifetime Achievement Award by AOGME

It has been a lifetime of service to osteopathic medicine and graduate medical education for Lisa Nash, DO, MS-HPEd, FAAFP, and that remarkable career was honored by the Assembly of Osteopathic Graduate Medical Educators as she received their 2024 Special Lifetime Achievement Award as part of the Am...